Lanean...
Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities
Oncogenic mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS) occur in 15%–30% of non-small cell lung cancer (NSCLC). However, despite decades of intensive research, there is still no direct KRAS inhibitor with clinically proven efficacy. Considering its association with poor treatment re...
Gorde:
| Argitaratua izan da: | Acta Biochim Biophys Sin (Shanghai) |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Oxford University Press
2016
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4689161/ https://ncbi.nlm.nih.gov/pubmed/26578706 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/abbs/gmv118 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|